Product custom-nanocomposites-lipid-nanoparticle-composite-materials

Home > products > custom-nanocomposites> lipid-nanoparticle-composite-materials

Catalog	name	Description	price
R-Mcs-511	EGCG-CS-LIP	EGCG-CS-LIP/EGCG-chitosan liposomes (±100nm) are a nanoscale drug delivery system that combines the biological activity of epigallocatechin-3-gallate (EGCG) with the stability and targeting of chitosan. This system significantly improves its stability, encapsulation efficiency, and cellular uptake efficiency by encapsulating EGCG in the core of liposomes and modifying the surface of liposomes with chitosan.	price>
R-Mcs-519	Au/Cu/ZIF-8 loaded oxidized caryophyllene and cinnamic acid	Au/Cu/ZIF-8 loaded oxidized caryophyllene and cinnamic acid It is a composite material that integrates porous carriers, catalytic active sites, and natural active ingredients. Can be used in the fields of biomedicine, environmental governance, and food preservation. This product is only for scientific research and cannot be used on the human body.	price>
R-Mcs-525	Liposome loaded Ergothionine,100nm	Liposome loaded Ergothionine (100nm) is a nano delivery system that encapsulates the natural antioxidant Ergothionine in liposomes with a particle size of approximately 100 nanometers. It has high bioavailability and targeted protective effects, and has shown broad application prospects in anti-aging, neuroprotection, and inflammation regulation.	price>
R-Mcs-531	PEG-Ag₃PO₄ NPs loaded with dual drug CCCP+meropenem	PEG silver phosphate nanoparticles loaded with dual drug CCCP+meropenem is a synergistic antibacterial delivery system based on nanocarriers, which combines silver phosphate nanoparticles (Ag₃PO₄ NPs) modified with polyethylene glycol (PEG) with two active drugs - carbonyl cyanochlorophenylhydrazone (CCCP) and meropenem (MER), aiming to overcome the treatment challenges of multidrug-resistant bacteria, especially carbapenem resistant Escherichia coli.	price>
R-Mcs-534	HA-Fe-PCN 224@Au@LAT1-IN-1	HA-Fe-PCN 224@Au@LAT1-IN-1/Hyaluronic acid modified Fe-PCN 224@Au@LAT1-IN-1 is a highly functional multi-level nanocomposite system that integrates advanced features such as targeted delivery, photodynamic/chemodynamic therapy, surface enhanced Raman detection, and intelligent response. It is specifically designed for integrated precision diagnosis and treatment of tumors.	price>
R-GHLS-100NM	Calcein Liposome （100nm）	Calcein Liposome from ruixi.Compared with the aqueous solution of calcein, the liposome can greatly increase the amount of calcein in the passive transmembrane, which is mainly distributed in lysosomes. The small molecule water-soluble drugs can change the way of entering cells, improve the ability of entering cells and affect the intracellular distribution.	price>
R-R-5665	HSPC/Chol/DSPE-mPEG2000/DSPE-mPEG2000-maleimide (50/45/4/1, mol/mol) Liposomes	HSPC/Chol/DSPE-mPEG2000/DSPE-mPEG2000-maleimide (50/45/4/1, mol/mol) Liposomes. PEGylated liposomes containing free maleimide functional group for maleimide-thiol conjugation. The liposomes are co-formulated with 1 mol% DSPE-mPEG2000-maleimide, and supplied in a pH-optimized buffer for direct conjugation of the thiol-containing molecule of choice. Conjugation can be achieved by incubating the liposomes with the activated thiol-containing compound which has been reduced by a disulfide bond reducing agent such as (tris(2-carboxyethyl)phosphine) (TCEP), which can be purchased as an add-on.	price>
R-R-5666	Tanespimycin (17-AAG) Liposomes, Formulation XT28.1	Tanespimycin (17-AAG) Liposomes, Formulation XT28.1. PEGylated liposomes containing Hsp90 inhibitor Tanespimycin (17-AAG). Tanespimycin exhibits 100-fold higher binding affinity to HSP90 derived from tumor cells vs normal cells, and induces apoptosis, necrosis, autophagy, and mitophagy. Tanespimycin is insoluble in aqueous media. This product is a pre-formulated liposomal version of Tanespimycin which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.	price>
R-R-5667	DT-061 (SMAP) Liposomes, Formulation TT-40	DT-061 (SMAP) Liposomes, Formulation TT-40. PEGylated liposomes containing PP2A activator DT-061 (SMAP). DT-061 is an activator of protein phosphatase 2A (PP2A). PP2A regulates many cellular signaling pathways including MAPK/ERK, Wnt/β-catenin, Akt/mTOR, GSK3β, p53/apoptosis, cell cycle, and others. This product can be used in vitro or in vivo for studying the effects of PP2A activation and could be applied to preclinical therapy of KRAS-mutant and MYC-driven tumors. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.	price>
R-R-5668	Liposomes for Loading Hydrophobic Drugs	Liposomes for Loading Hydrophobic Drugs (5.0mL). This pre-formed liposome product is created for post loading of hydrophobic small molecule compounds into liposomes. The process of drug incorporation is very straight-forward. Then simply add an aliquot of drug solution (prepared in a water-miscible solvent such as ethanol, DMSO and etc.) into the liposome suspension. The drug molecules can be incorporated into the lipid bilayers by the nature of hydrophobic interactions. The drug solubility therefore could be significantly enhanced. Liposomal drug concentration of 1-2 mg/mL could be achieved for most lipophilic drugs. PEGylation of the liposomes provides not only better formulation stability but also the potential of achieving prolonged in vivo blood circulation. The finished drug loaded formulations are suitable for either in vitro testing or in vivo studies.	price>

...